Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

开始日期2025-02-01

申办/合作机构

The General Hospital Corp.

[+1]

CTRI/2024/11/076293

/ Not yet recruiting临床2/3期

A Randomized, double-blind, two arm, crossover design to assess the bioavailability of Liposomal berberine and berberine formulations in otherwise healthy volunteers - NIL

开始日期2024-11-15

申办/合作机构

Specnova LLC

ChiCTR2400091126

/ Recruiting早期临床1期IIT

Pilot study of berberine combined with methimazole in the treatment of newly diagnosed Graves' disease

开始日期2024-10-21

申办/合作机构

中山大学附属第一医院

100 项与头孢羟氨相关的临床结果

登录后查看更多信息

100 项与头孢羟氨相关的转化医学

登录后查看更多信息

100 项与头孢羟氨相关的专利（医药）

登录后查看更多信息

941

项与头孢羟氨相关的文献（医药）

2025-01-02·Molecular Cancer Therapeutics

The Discovery of a Potent PARP1 Inhibitor Senaparib

Article

作者: Cai, Sui X. ; Wang, Xiaozhu ; Ma, Ning ; Guo, Mingchuan ; Jiang, Yangzhen ; Tian, Ye E.

AbstractPARP1 is a critical enzyme involved in DNA damage repair. It belongs to a superfamily of proteins and catalyzes poly(ADP-ribosyl)ation (PARylation). PARP1 inhibitors are effective to treat tumors that have homologous recombination deficiency such as those with BRCA1/2 mutations. The PARP1 inhibitors that have been approved by FDA inhibit both PARP1 and PARP2. PARP2 has also been suggested to play a similar function in DNA repair as PARP1. In addition to inhibiting PARP1 enzymatic activities, PARP1 inhibitors cause the PARP1 enzyme to be “trapped” on DNA, stalling the DNA replication fork and eventually causing double-strand DNA breaks and cell death. Here, we report a PARP1 inhibitor, Senaparib, which has a novel chemical structure and high potency inhibiting PARP1/2 enzymes. Senaparib was highly potent in cell viability tests against tumor cells with BRCA1/2 mutations. It was efficacious in cell line-derived and patient-derived xenograft models in tumors harboring BRCA1/2 mutations. In combination studies, Senaparib used with temozolomide had shown strong synergistic cytotoxicity in both in vitro and in vivo experiments. Senaparib represents a novel class of PARP1 inhibitors that can be used for the treatment of cancer. A phase III clinical study of Senaparib for maintenance treatment following first-line chemotherapy in patients with advanced ovarian cancer has met its primary endpoint, and a new drug application of Senaparib has been accepted by the National Medical Products Administration of China for review.

2025-01-01·Laboratory Investigation

Cefadroxil Targeting of SLC15A2/PEPT2 Protects From Colistin Nephrotoxicity

Article

作者: Valiño, Lara ; Sanz, Ana B ; Pintor-Chocano, Aranzazu ; Sanchez-Niño, Maria Dolores ; Fernandez-Prado, Raul ; Sanz, Ana B. ; Ortiz, Alberto

Acute kidney injury (AKI) and chronic kidney disease (CKD) are considered interconnected syndromes, as AKI episodes may accelerate CKD progression, and CKD increases the risk of AKI. Genome-wide association studies (GWAS) may identify novel actionable therapeutic targets. Human GWAS for AKI or CKD were combined with murine AKI transcriptomics data sets to identify 13 (ACACB, ACSM5, CNDP1, DPEP1, GATM, SLC6A12, AGXT2L1, SLC15A2, CTSS, ICAM1, ITGAX, ITGAM, and PPM1J) potentially actionable therapeutic targets to modulate kidney disease severity across species and the AKI-CKD spectrum. Among them, SLC15A2, encoding the cell membrane proton-coupled peptide transporter 2, was prioritized for data mining and functional intervention studies in vitro and in vivo because of its known function to transport nephrotoxic drugs such as colistin and the possibility for targeting with small molecules already in clinical use, such as cefadroxil. Data mining disclosed that SLC15A2 was upregulated in the tubulointerstitium of human CKD, including diabetic nephropathy, and the upregulation was localized to proximal tubular cells. Colistin elicited cytotoxicity and proinflammatory response in cultured human and murine proximal tubular cells that was decreased by concomitant exposure to cefadroxil. In proof-of-concept in vivo studies, cefadroxil protected from colistin nephrotoxicity in mice. The GWAS association of SLC15A2 with human kidney disease may be actionable and related to the modifiable transport of nephrotoxins causing repeated subclinical episodes of AKI and/or chronic nephrotoxicity.

2024-12-24·Analytical Chemistry

Self-Activated Cascade-Tailored Small Molecule for Cancer Therapy, Companion Diagnostics, and “Theranostic Correlation” Evaluation

Article

作者: Yang, Yanyun ; Dong, Ling ; Yuan, Yue ; Wang, Chenchen ; Ling, Bo ; Liu, Zhengjie ; Liu, Pingping ; Tong, Tong ; Wang, Congxiao

Companion diagnostics (CDx) have emerged as valuable tools for monitoring biomarkers essential for drug activation and therapeutic response, enabling personalized treatment strategies. However, the current FDA-approved CDx is limited to in vitro testing, making it challenging to assess the real-time drug efficacy. Moreover, evaluation of treatment responses solely based on drug release or activation may disregard tumor heterogeneity. To address these challenges, we have developed a cascade-responsive small molecule Cbl-DEVD-Hcy for simultaneous cancer therapy and the timely evaluation of therapy effectiveness in vivo. Upon cleavage by tumor-cell-overexpressed carboxylesterase, chlorambucil (Cbl) can be released to induce tumor cell apoptosis and activate caspase-3. This activation triggers the production of the near-infrared dye Hcy-NH₂, generating both near-infrared fluorescence and photoacoustic signals for monitoring the apoptosis process. The excellent "theranostic correlation" between the imaging signal and therapeutic response, as demonstrated in orthotopic breast tumors, highlights the potential of Cbl-DEVD-Hcy for effective tumor therapy and precise CDx in the body.

518

项与头孢羟氨相关的新闻（医药）

2025-01-20

·米内网

独家品种飙涨95%，头孢类市场巨变！齐鲁、太极、倍特大爆发，重磅注射剂备战国采

精彩内容近日有消息指，国家层面将在2025上半年开展第十一批药品集中采购，头孢类作为国采“常客”，再有两款重磅注射剂备战。2024年Q1-Q3在重点省市公立医院终端，头孢类的销售额继续下滑，TOP20品种大洗牌，6个昔日亿级品种跌落神坛。近几年，太极集团、齐鲁制药、倍特药业逆势拼搏，成绩亮眼，济川药业等11家药企在2024年正式入局，9个重磅新品将迎来首家获批，市场新一轮激战备受瞩目。头孢类市场“三连跌”！太极、齐鲁、倍特逆势拼搏头孢类是临床常用药，一直是全身用抗细菌药最热门的小类，近几年在限输限抗、国采、地方集采等系列政策的影响下，该类药物的市场份额不断下滑。2024年Q1-Q3在重点省市公立医院终端，头孢类的销售额继续下滑，跌幅超过10%，在全身用抗细菌药市场的份额跌至38.33%，为近十年新低，形势十分严峻。图1：近几年头孢类的销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局从用药途径来看，注射药品的占比依然在八成以上，2024年Q1-Q3销售额下滑了17.25%；内服药品的占比回升至12%以上，2024年Q1-Q3销售额大涨了33.46%。在重点省市公立医院终端，头孢类的销售峰值出现在2017年，当年TOP10集团（二级，下同）合揽超过50%的市场，而2024年Q1-Q3的TOP10集团合揽的市场份额升至60%以上，市场集中度有了大幅提升。表1：2017年及2024年Q1-Q3头孢类TOP5集团的变化情况来源：米内网重点省市公立医院药品终端竞争格局太极集团在2017年排在TOP7集团，市场份额在3.02%。近几年太极集团的头孢类销售额有升有降，排名在2022年升上TOP3后一直稳守高位，2024年Q1-Q3的市场份额已超过了5%。齐鲁制药的头孢类销售额则在2021年起迎来爆发期，最近四年的增长率分别为353.55%、301.19%、89.66%、56.69%，成功在2024年Q1-Q3升上TOP4集团，市场份额从2017年的0.18%一路狂飙至2.77%，发展势头勇猛。倍特药业也是近几年的黑马之一，集团的头孢类在2018-2022年实现了快速增长，增长率分别为28.50%、55.09%、18.64%、88.31%、107.48%，市场份额在2022年升上2.62%。近两年倍特药业的头孢类销售额出现了下滑态势，但市场份额依然保持在2%以上，2024年Q1-Q3排在TOP8集团，2025年能否止跌回升，我们拭目以待。 6个亿级品种陨落，独家品种飞涨95%，最新TOP20出炉 2018年4+7城市试点为国家集中带量采购工作掀开序幕，头孢类作为临床常用药，每一批次均有涉及，据统计，前十批国采已涉及19个畅销品种，“以价换量”进一步加快市场洗牌。表2：2017年及2024年Q1-Q3头孢类TOP20品种变化情况来源：米内网重点省市公立医院药品终端竞争格局 2017年TOP20品种合计市场份额为87.54%，仅1个品种市场份额超过10%，2024年Q1-Q3的TOP20品种合计市场份额超过93%，两个品种的市场份额在10%以上，品种的市场集中度也在不断提升。对比2017年的TOP20品种，仅有头孢哌酮舒巴坦和拉氧头孢在2024年Q1-Q3的排名不变。2024年Q1-Q3头孢哌酮舒巴坦以24.47%的市场份额遥遥领先，注射用头孢哌酮钠舒巴坦钠在第八批国采（2023年4月）中标，该品种的销售额大跌了29.88%；2024年Q1-Q3拉氧头孢的市场份额保持在10%以上，销售额跌了26.32%，注射用拉氧头孢钠在第十批国采（2024年12月）中标，该品种后续会否“跌不停”，我们将继续观察。六大潜力品种备受关注：头孢他啶阿维巴坦和头孢克洛跻身TOP10品种，2024年Q1-Q3的销售额增长率分别为26.26%、16.37%；独家品种头孢托仑匹酯的销售额2022年起连连暴涨，近三年的增长率分别为319.14%、141.36%、95.36%，2024年Q1-Q3排名TOP13；头孢泊肟酯2024年Q1-Q3销售额增长了21.78%，排名TOP14；头孢拉定和头孢曲松他唑巴坦位列TOP18、TOP20品种，两个品种2024年Q1-Q3的销售额有下滑。图2：头孢他啶阿维巴坦的销售情况（单位：万元）来源：米内网重点省市公立医院药品终端竞争格局辉瑞的注射用头孢他啶阿维巴坦钠在2019年进入中国市场，齐鲁制药在2021年拿下国内首仿+首家过评，2023年科伦药业的注射用头孢他啶阿维巴坦钠/氯化钠注射液拿下国内首仿+首家过评，目前国内市场上的头孢他啶阿维巴坦涉及两个产品，共14家竞争企业。值得注意的是，6个亿级品种跌出了TOP20榜单：头孢克肟2017年销售额为4.0亿元，2024年Q1-Q3跌至3800万元，最新排名为TOP21；头孢西丁2017年销售额为5.4亿元，2024年Q1-Q3跌至2100万元，最新排名为TOP28；头孢孟多2017年销售额为5.3亿元，2024年Q1-Q3也跌至了2000万元，最新排名为TOP29；头孢甲肟2017年销售额为2.9亿元，2024年Q1-Q3跌至1400万元，最新排名为TOP30；头孢地嗪2017年销售额为3.0亿元，2024年Q1-Q3跌至500万元，最新排名为TOP33；头孢替唑2017年销售额为2.6亿元，2024年Q1-Q3跌至100万元，最新排名为TOP39……昔日畅销大品种跌落神坛，市场洗牌十分严重。中药龙头入局抢食，葫芦娃、科伦抢重磅首仿 2015年开局，头孢类市场再迎7个新产品，包括了齐鲁制药的注射用头孢哌酮钠舒巴坦钠、瑞阳制药的注射用头孢他啶阿维巴坦钠、华润三九的注射用头孢唑肟钠、国药集团的头孢丙烯干混悬剂和头孢地尼颗粒、海南广升誉制药的头孢羟氨苄片、正大天晴药业集团的注射用头孢他啶阿维巴坦钠，该类药物市场持续有新的入局者。表3：2024年获批的头孢类新产品情况来源：米内网中国申报进度（MED）数据库据统计，2024年全年获批了49个头孢类新产品（按产品名+企业名统计），其中注射用头孢唑肟钠有11家企业新获批，是大热品种。从企业集团来看，齐鲁制药共拿下8个新品遥遥领先，包括了头孢克肟颗粒、头孢地尼胶囊、头孢地尼颗粒、注射用盐酸头孢替安、头孢克洛干混悬剂、头孢泊肟酯片、头孢克洛胶囊、头孢泊肟酯干混悬剂。值得注意的是，有11家药企在2024年正式入局头孢类市场，包括了中药龙头济川药业。2024上半年在中国三大终端六大市场，济川药业是中成药TOP10集团（二级），近几年公司在化药市场不断有新品获批，2024年12月公司的注射用头孢唑肟钠获批，成功为公司打开头孢类市场大门。表4：即将上市的部分头孢类重磅新品来源：米内网中国申报进度（MED）数据库据统计，2018年至今头孢类有120多个受理号申请上市在审，其中9个重磅新品即将迎来首家获批，包括了两个原研药注射用头孢洛生他唑巴坦钠和注射用头孢德罗。资料显示，注射用头孢洛生他唑巴坦钠在2014年获得FDA批准上市，注射用头孢德罗在2019年获得FDA批准上市，米内网预计上述两个产品有望在2025年下半年在中国获批。目前市场上的头孢托仑匹酯制剂均为明治的独家产品，近三年在重点省市公立医院终端的销售额持续飞涨，市场潜力不容小觑。福安药业庆余堂制药、北京诚济制药、海南葫芦娃药业集团将争夺头孢托仑匹酯颗粒的国内首仿，而头孢妥仑匹酯片仅有福安药业庆余堂制药申报仿制上市在审，该品种国内首仿属谁，或将于2025年揭开谜底。注射用头孢唑肟钠/氯化钠注射液是一款粉液双室袋产品，科伦药业已成为多室袋制剂的行业龙头，无论最终能否抢下国内首仿，都将为公司的产品线再添重磅一员。国产1类新药方面，白云山制药总厂的1类新药注射用头孢嗪脒钠在2017年获批临床，该新药在2024年4月启动了敏感菌引起的社区获得性肺炎的II期临床，同年11月第一例受试者成功入组。 2025上半年启动第十一批国采，两款重磅注射剂备战近日在国家医保局的新闻发布会上获悉，国家层面将在2025上半年开展第十一批药品集中采购，市场再度掀起热浪。截至2025年1月20日，头孢类过评（含视同过评）的产品超过60个（按产品名统计，下同），前十批国采已有28个产品中标，目前竞争企业（过评+原研）≥7家的有注射用头孢唑肟钠和注射用头孢他啶阿维巴坦钠。表5：竞争企业（过评+原研）≥7家的头孢类产品来源：米内网重点省市公立医院药品终端竞争格局随着国产品牌陆续获批，注射用头孢他啶阿维巴坦钠在重点省市公立医院终端的销售额持续暴涨，2024年Q1-Q3原研企业辉瑞的市场份额跌至88.35%，齐鲁、科伦、南京优科制药等国内药企快速抢占市场，若该产品能纳入第十一批国采，国产品牌有望借力再创新佳绩。资料来源：米内网数据库等注：米内网重点省市公立医院化学药终端竞争格局数据库是以20+省市，近700家样本省市公立医院的化学药采购数据为基础，对化学药全品类进行连续监测的样本省市样本医院数据库；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月20日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购上市批准核酸药物申请上市医药出海

2025-01-17

·Business Wire

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for OJEMDA™ (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients

BOSTON--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Day One Biopharmaceuticals’ OJEMDA, a type II RAF inhibitor, for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. FoundationOne CDx is the first and only companion diagnostic for OJEMDA. pLGG is the most common brain tumor diagnosed in children. 1,2 In this patient population, a BRAF alteration is detected in up to 75 percent of cases. Previously, no FDA-approved treatment options were available targeting tumors harboring BRAF fusions, which represent 80% of BRAF altered patients. 3,4,5,6,7 “Foundation Medicine is proud to partner with Day One to help healthcare providers connect pediatric patients and families with this treatment option,” said Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine. “Our high-quality tissue-based companion diagnostic test is uniquely capable of detecting both BRAF V600 mutations and fusions which enables providers to gain the complete genomic picture of their patient’s tumor and guide treatment decision making.” Foundation Medicine has sequenced over 2,200 pediatric central nervous system tumors 8 and is the only company to offer both tissue and blood-based comprehensive genomic profiling tests that are approved by the FDA. Using a tissue sample, the FDA-approved FoundationOne CDx test analyzes more than 300 cancer-related genes in a patient’s tumor. Foundation Medicine is the global leader in approved companion diagnostic indications. Foundation Medicine also has 40% of all approved companion diagnostic indications for next-generation sequencing (NGS) testing in the United States and Japan. 9,10 “Historically, pediatric patients with pLGG have faced overwhelming side effects, both near- and long-term, from aggressive treatments like chemotherapy and radiation,” said David Arons, president and chief executive officer at the National Brain Tumor Society. “We are thrilled to see that there are now additional treatment options available for these children, as well as an FDA-approved companion diagnostic test to help identify more patients who may benefit from Day One’s therapy.” Foundation Medicine and FoundationOne ® are registered trademarks of Foundation Medicine, Inc. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn and X . About FoundationOne®CDx FoundationOne®CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com . 1 Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 21, V1–V100 (2019). 2 Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathologica Communications 2020 8:1 8, 1–22 (2020). 3 Sun Y, Alberta JA, Pilarz C. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol . 2017;19(6):774-785. doi:10.1093/neuonc/now261 4 Penman CL, Faulkner C, Lowis SP, Kurian KM. Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol . 2015;5:54. doi:10.3389/fonc.2015.00054 5 Ryall S, Zapotocky M, Fukuoka K, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell . 2020;37(4):569-583.e5. doi:10.1016/j.ccell.2020.03.011 6 Cohen AR. Brain tumors in children. N Engl J Med . 2020; 386(20):1922-1931. doi:10.1056/NEJMra2116344 7 Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol . 2017;35(25):2934-2941. doi:10.1200/JCO.2016.71.8726 8 FoundationCore® Database, March, 2024 9 List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools . 10 List of Vitro Companion Diagnostics or Medical Devices (CDx Products) Approved in Japan. https://www.pmda.go.jp/files/000264514.pdf

诊断试剂

2025-01-16

·米内网

【聚焦】暴涨758%“流感新宠”，河南药企拿下

精彩内容近日，国家药监局官网显示，郑州泰丰制药申报的4类仿制药玛巴洛沙韦片获批生产并视同过评，为国产第2家获批。该药为全新机制的抗流感药，原研产品2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过5亿元，同比涨约758%。冬春季节，流感进入高发季。有媒体报道称，近期有多个药店的玛巴洛沙韦库存紧张。目前，奥司他韦还是抗流感的主流用药，但玛巴洛沙韦的销售增长速度非常快。玛巴洛沙韦是一款帽状结构依赖型核酸内切酶抑制剂，为全新机制的抗流感新药。原研产品于2021年4月获批进入中国市场，上市仅8个月后就通过谈判纳入国家医保乙类目录。米内网数据显示，近年来中国三大终端六大市场玛巴洛沙韦片销售额快速增长，2022年尚未超过1亿元，2023年就已突破5亿元，同比涨约758%，2024上半年以约24%的增速继续增长。近年来中国三大终端六大市场玛巴洛沙韦片销售情况（单位：万元）来源：米内网格局数据库玛巴洛沙韦的市场潜力引来了众多跟随者。2022年10月，石药集团欧意药业拿下该产品国内首仿+首家过评；郑州泰丰制药的产品于近日获批，为国产第2家。此外，浙江普利药业的产品以新分类报产在审。郑州泰丰制药成立于2005年，是一家以生产化学药口服制剂为主的现代化制药企业，目前拥有30余个品种的生产批文，涵盖片剂、散剂、硬胶囊剂等剂型。目前公司有12个品种以新注册分类报产，其中玛巴洛沙韦片、盐酸西那卡塞片、拉米夫定片、富马酸替诺福韦二吡呋酯片4个品种已获批生产并视同过评。在审的8个品种中，盐酸纳呋拉啡口崩片、甲磺酸溴隐亭片等暂无国产仿制药获批。郑州泰丰制药新分类报产且在审的品种来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月16日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

100 项与头孢羟氨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	头孢羟氨	J01DB05	DB01140

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
咽炎	美国	Lupin Ltd	2008-02-21
细菌感染	中国	黑龙江诺捷制药有限责任公司	1986-01-01
细菌感染	中国	葵花药业集团股份有限公司	1986-01-01
细菌感染	中国	牡丹江灵泰药业股份有限公司	1986-01-01
细菌感染	中国	哈药集团股份有限公司	1986-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


1466 (SITC2024)	临床1/2期	黑色素瘤辅助 BRAF-V600E	-	Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg	糧衊繭艱顧網糧願顧窪(鑰鏇艱襯膚遞鏇鏇遞獵) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities 鹹鑰獵膚顧築範衊鏇艱 (艱餘遞鬱衊淵觸衊餘襯 )	积极	2024-11-05
				Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg
DDW2024	N/A	腺瘤	-	Compound Berberine Hydrochloride	鏇鏇選鏇窪鑰廠鑰鑰淵(窪範鏇鹽簾糧積艱膚廠) = 遞鬱獵蓋糧糧淵觸製淵鑰膚糧築願糧簾積糧艱 (壓築簾積遞憲願築鬱觸 )	积极	2024-05-19
AAAAI2024	N/A	过敏	-	Cefazolin	觸襯遞製淵鹹衊憲艱選(製願製鹽膚製簾鑰衊襯) = 鹽觸獵鑰願鑰鏇艱艱餘淵醖憲積壓夢壓鹽壓遞 (製繭簾糧繭艱鏇網糧淵 )	-	2024-02-23
				Cefoxitin	觸襯遞製淵鹹衊憲艱選(製願製鹽膚製簾鑰衊襯) = 願構糧衊網襯窪餘膚遞淵醖憲積壓夢壓鹽壓遞 (製繭簾糧繭艱鏇網糧淵 )
DDW2022	N/A	转移性胰腺癌	-	Berberine	繭鬱膚襯淵觸蓋繭襯選(獵艱衊鬱醖簾襯膚鹹衊) = 衊簾壓齋鹹鹹淵糧蓋壓糧製窪齋積簾積簾遞網 (觸糧襯網膚膚選鏇願築 )	积极	2022-05-24
				Vehicle	繭鬱膚襯淵觸蓋繭襯選(獵艱衊鬱醖簾襯膚鹹衊) = 艱餘製範憲簾積鹹衊憲糧製窪齋積簾積簾遞網 (觸糧襯網膚膚選鏇願築 )
Tandem Meetings ASTCT and CIBMTR2013	临床1期	-	30	CDX-301 1 mcg/kg	製願範淵餘簾齋遞憲壓(憲鬱鹹膚築網鹹夢廠窪) = one HV with a remote history of community acquired pneumonia was hospitalized with community acquired pneumonia which developed on study day 12; the event responded rapidly to antibiotic treatment and fully recovered within 2 weeks, but was considered a dose-limiting toxicity given the temporal association with CDX-301 administration 膚繭夢鹽餘製膚觸製廠 (積鬱鹽襯顧繭壓獵簾獵 )	积极	2013-02-01
				CDX-301 3 mcg/kg
NCT00835081 (CTgov)	临床1期	-	26	Cefadroxil (Cefadroxil (Test))	(蓋顧繭鑰夢繭醖鏇鹹鬱) = 積餘繭築構蓋鑰醖繭醖淵憲壓夢選構鹽願齋觸 (鹽範餘鏇蓋選艱醖膚夢, 鏇艱憲獵鏇夢積鹹築積 ~ 廠繭衊鏇糧繭淵鹹襯繭) 更多	-	2009-07-21
				Duricef (Duricef® (Reference))	(蓋顧繭鑰夢繭醖鏇鹹鬱) = 顧淵網製淵襯繭襯遞顧淵憲壓夢選構鹽願齋觸 (鹽範餘鏇蓋選艱醖膚夢, 膚餘艱糧觸夢衊觸願襯 ~ 構艱膚窪顧襯範餘積淵) 更多
NCT00834275 (CTgov)	临床1期	-	26	Cefadroxil (Cefadroxil (Test))	(淵膚顧選遞壓糧憲鑰鹽) = 繭繭廠築鹽鏇網範獵網築鏇夢糧淵衊鹽網選願 (積繭齋衊繭襯膚壓繭範, 鬱襯觸鑰齋齋範壓選淵 ~ 鑰簾鹹積繭鬱衊網願艱) 更多	-	2009-07-21
				Duricef (Duricef® (Reference))	(淵膚顧選遞壓糧憲鑰鹽) = 鹹憲夢顧壓築襯鏇遞壓築鏇夢糧淵衊鹽網選願 (積繭齋衊繭襯膚壓繭範, 顧襯網鹽夢鏇鹽觸鬱鹽 ~ 鬱壓蓋膚願壓範淵齋築) 更多